ライフサイエンスコーパス: enrolled patients

1 Enrolled patients underwent perimetry at baseline and annual

2 Enrolled patients were of diverse ethnic backgrounds and cove

3 Enrolled patients were randomly assigned (1:1) centrally by u

4 Enrolled patients with mUC (n = 155) were heavily pretreated,

5 Among 10 102 enrolled patients, 6135 patients were treated at hospitals ra

6 320 isolates from 379 enrolled patients were available with susceptibility to piper

7 Of the 389 enrolled patients, 133 (34.2%) died within 180 days of ICU ad

8 Among 40 enrolled patients, 27 were assigned to focused ultrasound sub

9 Of the 40 enrolled patients (78% men; median age, 63 years), 33 (83%) c

10 Thirty eight of the 44 enrolled patients completed the study, 17 from the bovine gro

11 Between April 6, 2017, and Nov 26, 2018, 71 (96%) of 74 enrolled patients received at least one dose of UGN-101.

12 In 8 enrolled patients, the mean number of attacks normalized per

13 All enrolled patients received at least one dose of study treatme

14 All enrolled patients were included in the primary and safety ana

15 All enrolled patients who received at least one dose of cabozanti

16 tuzumab in the per-protocol pharmacokinetic population (all enrolled patients who adhered to prespecified criteria for ph

17 f women diagnosed with breast cancer at age <= 40 years and enrolled patients between 2006 and 2016 (N = 1,302).

18 , and procedure frequencies received at these facilities by enrolled patients.

19 In the first 55 consecutively enrolled patients with RET-mutant medullary thyroid cancer wh

20 Four enrolled patients did not undergo the protocol because of med

21 O Prospective Registry (EPROMPT; NCT03423459) prospectively enrolled patients with symptomatic severe aortic stenosis to

22 We prospectively enrolled patients with K. aerogenes or Enterobacter cloacae c

23 This observational, prospective, non-interventional study enrolled patients aged >=18 years scheduled to receive DEX im

24 Methods: A multicenter retrospective study enrolled patients who had undergone PSMA PET for CRPC, had pr

25 This study enrolled patients presenting to the emergency department with

26 for a randomised, open-label, phase 3 study (RESPONSE) that enrolled patients at 109 sites across North America, South Am

27 EV-101 is a phase I dose escalation/expansion study that enrolled patients with Nectin-4-expressing solid tumors (eg,

28 ndomised, open-label, active-controlled, phase 3 trial that enrolled patients between Feb 9, 2015, and July 14, 2016, at

29 The enrolled patients underwent 215 US, 167 CT, and 69 MRI examin

30 Of the enrolled patients (19 sites throughout India; n = 250), 84 ha

31 The median age of the enrolled patients was 13 years (IQR 8-15).

32 Of the enrolled patients, 83.4% completed the 24-month trial.

33 The multicentre, open-label, phase 1-2 AG221-C-001 trial enrolled patients with advanced haematological malignancies (

34 ed, phase-3b, multicentre (168 sites in 26 countries) trial enrolled patients aged at least 18 years with active psoriati

35 This multicentre, open-label extension (OLE) trial enrolled patients at 43 hospitals or clinical centres in 19 c

36 Two enrolled patients died within 3 months of treatment from pre-

37 nurses, social workers, and community health workers visits enrolled patients to coordinate outpatient care and link them

38 We enrolled patients (aged 3-64 years) presenting to two Kathman

39 We enrolled patients admitted to hospital with suspected or conf

40 We enrolled patients between Oct 27, 2010, and Feb 13, 2013, and

41 We enrolled patients who underwent kidney transplantation and we

42 We enrolled patients with a controlled primary malignancy and 1-

43 We enrolled patients with atherosclerotic cardiovascular disease

44 We enrolled patients with locally advanced and/or metastatic ana

45 We enrolled patients with metastatic RCC with no prior checkpoin

46 tudy done in 48 acute care hospitals in eight countries, we enrolled patients with acute ischaemic stroke due to large ve

47 Last, we enrolled patients with stage D HF and sampled their blood bef

48 is multicenter, prospective, observational cohort study, we enrolled patients aged 6 months to 18 years with newly placed

49 lticenter, non-inferiority, randomized controlled trial, we enrolled patients with culture-confirmed melioidosis who had

50 In this double-blind, placebo-controlled, phase 2 trial, we enrolled patients with or without heterozygous familial hyper